Actively Recruiting
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Led by Ruijin Hospital · Updated on 2024-11-19
15
Participants Needed
1
Research Sites
398 weeks
Total Duration
On this page
Sponsors
R
Ruijin Hospital
Lead Sponsor
S
Shanghai Houchao Biotechnology Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
CONDITIONS
Official Title
Study of High Efficient Killing Cell Therapy for Advanced NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 18 to 70 years
- Life expectancy of at least 3 months
- Pathologically confirmed non-small cell lung cancer
- Failure of previous standard chemotherapy and targeted therapy
- Karnofsky performance status of 0 to 1
- Adequate organ functions
You will not qualify if you...
- Pregnant or breastfeeding women
- Patients with T cell lymphoma, syphilis, AIDS, or co-infections
- History of severe allergies or highly allergic patients
- Severe liver or kidney dysfunction
- Severe autoimmune disease or treatment with immunosuppressive agents
- Uncontrolled severe infection or high fever
- Organ transplant recipients or candidates
- Presence of brain metastasis
- Severe blood clotting disorders such as hemophilia
- Inability to understand, consent, or participate voluntarily in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital
Shanghai, China
Actively Recruiting
Research Team
L
Lei H Du, M.S
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here